Company Search
CEO Interview
Drive With Dynacor Video Series
TSX_DNG on 2012-05-17 10:38Dynacor has released a new video series called the "Drive With Dynacor". http://youtu.be/seFbg2CXt6U
NAI Blog
My Top Junior Oil Stock in the Permian Basin “Tight” Oil Play Keith Schaefer on 2012-04-26 07:40:54Part 2: The Permian Basin – Cline Shale Resource Play
Company News - Company Data
Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013
Posted 2012-05-16 23:58NAI Editing
today reported financial results for its fourth quarter and fiscal year ended March 31, 2012, and provided financial expectations for its fiscal year 2013, which will be the first full fiscal year of Alkermes plc Concludes Secondary Offering of 24.15m Ordinary Shares
Posted 2012-03-14 00:54NAI Editing
-Biopharmaceutical company Alkermes plc (NASDAQ:ALKS) reported on Tuesday the completion of an underwritten public offering of 24,150,000 ordinary shares held by Elan Corporation plc's subsidiary, at Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan
Posted 2012-03-13 05:47NAI Editing
today announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share, whiAlkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan
Posted 2012-03-08 01:23NAI Editing
today announced the pricing of an underwritten public offering of 21,000,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share.Alkermes Appoints Mark Stejbach as Chief Commercial Officer
Posted 2012-03-05 00:57NAI Editing
today announced that Mark Stejbach has been appointed Chief Commercial Officer. In this newly created role, Mr.Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results
Posted 2012-02-02 00:32NAI Editing
today reported financial results for its third quarter of fiscal 2012, which ended on Dec. 31, 2011.Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder
Posted 2012-01-04 01:21NAI Editing
today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapieAlkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia
Posted 2011-12-19 00:36NAI Editing
today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia.Alkermes plc Reports Second Quarter Fiscal 2012 Financial Results
Posted 2011-11-02 23:54NAI Editing
today reported financial results for its second quarter of fiscal 2012, which ended on Sept. 30, 2011.Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
Posted 2011-10-02 23:48NAI Editing
today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation (OIC).
Posted 2012-05-16 23:58
NAI Editingtoday reported financial results for its fourth quarter and fiscal year ended March 31, 2012, and provided financial expectations for its fiscal year 2013, which will be the first full fiscal year of Alkermes plc Concludes Secondary Offering of 24.15m Ordinary Shares
Posted 2012-03-14 00:54
NAI Editing-Biopharmaceutical company Alkermes plc (NASDAQ:ALKS) reported on Tuesday the completion of an underwritten public offering of 24,150,000 ordinary shares held by Elan Corporation plc's subsidiary, at Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan
Posted 2012-03-13 05:47
NAI Editingtoday announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share, whiAlkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan
Posted 2012-03-08 01:23
NAI Editingtoday announced the pricing of an underwritten public offering of 21,000,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share.Alkermes Appoints Mark Stejbach as Chief Commercial Officer
Posted 2012-03-05 00:57
NAI Editingtoday announced that Mark Stejbach has been appointed Chief Commercial Officer. In this newly created role, Mr.Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results
Posted 2012-02-02 00:32
NAI Editingtoday reported financial results for its third quarter of fiscal 2012, which ended on Dec. 31, 2011.Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder
Posted 2012-01-04 01:21
NAI Editingtoday announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapieAlkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia
Posted 2011-12-19 00:36
NAI Editingtoday announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia.Alkermes plc Reports Second Quarter Fiscal 2012 Financial Results
Posted 2011-11-02 23:54
NAI Editingtoday reported financial results for its second quarter of fiscal 2012, which ended on Sept. 30, 2011.Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
Posted 2011-10-02 23:48
NAI Editingtoday announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation (OIC).